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CANCER AS A GENETIC DISEASE
The genetic basis of cancer was dis-
covered more than a century ago, when
David von Hansemann observed that
cells from various carcinoma samples
had chromosomal alterations. At the be-
ginning of the 20th century Theothor
Bovery suggested that cancer might re-
sult as a consequence of these chromo-
somal aberrations, laying the founda-
tions for viewing cancer as a genetic
disease (1). But the idea of cancer as a
genetic disease was not widely accepted
at that time. If cancer was caused by a
genetic mutation, it was not clear why
there was a delay of many years be-
tween the exposure to a mutagenic
agent and the onset of cancer, or why
the incidence of cancer increased so dra-
matically with age. Over time, the ob-
servations that no single gene defect
causes cancer and that several muta-
tions could be required for cancer to de-
velop explained the long latent period
of cancer and the age distribution of this
disease (2–4). In the second half of the
20th century, the idea that the develop-
ment of cancer required the acquisition
of several mutations began to be widely
accepted, and efforts were made to
identify which genes were involved in
carcinogenesis (5,6). In the 1980s the
first human oncogenes and tumor-sup-
pressor genes were discovered, and the
idea that cancer was caused by muta-
tions in these two types of genes was
gaining firm ground (7–11). Mutations
in oncogenes would increase the synthe-
sis of proteins that stimulate cell prolif-
eration, and mutations in tumor-sup-
pressor genes would result in the loss of
proteins that restrain cell proliferation
and induce apoptosis. The accumulation
of several mutations in these two types
of genes would allow cells to proliferate
in an uncontrolled fashion and would
lead to cancer. It was believed at that
time that cancer would be explained by
a relatively low number of mutations in
these genes, and that cancer would
eventually be treatable by reversing or
exploiting these genetic changes.
Molecular analyses of human tumors
carried out in the last decade have re-
vealed that the genetic alterations of
cancer cells are much more numerous
and unstable than previously thought
(12). For instance, by sampling colorec-
tal premalignant polyp and carcinoma
cell genomes, Stoler et al. (13) found that
the mean number of genomic changes
per carcinoma cell was approximately
11,000. In addition, much evidence has
accumulated stating that mutations
(changes in the DNA sequence) are not
the only cause of the altered gene ex-
pression of cancer cells. Epigenetic alter-
ations (heritable and reversible changes
other than the DNA sequence) and ane-
uploidy (numerical and structural ab-
normalities in chromosomes) are com-
mon alterations in tumor cells, which
modify gene expression and may also
play a crucial role in carcinogenesis
(14–18). Such is the genetic complexity
and variability of tumor cells, that the
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idea of understanding cancer in terms of
changes in specific genes is losing
ground in favor of proposals that seek
to rationalize cancer in terms of a lim-
ited number of acquired phenotypes
(the so-called hallmarks of cancer) and
altered cellular pathways (19–21). We
are beginning to realize that the high
genetic variability of tumor cells is a se-
rious obstacle for the design of gene-
based therapies that may have a major
impact on cancer mortality (12,21).
Despite the complexity and variability
of the cancer genome, much research is
devoted to characterizing the genetic
profile of tumors to rationalize and per-
sonalize cancer therapy (22–24). The re-
cent approval of several cancer-targeted
therapies (therapies that are intended to
target the molecular defects of cancer
cells specifically) indicate that the altered
genome of cancer cells can be exploited
therapeutically (25). The landmark event
in this new field was the development of
imatinib mesylate (Gleevec) for the treat-
ment of chronic myeloid leukemia
(CML). This drug was developed as a se-
lective inhibitor of the kinase BCR-ABL,
the fusion protein product of a chromo-
somal translocation that is involved in
the pathogenesis of CML. Clinical trials
revealed that imatinib mesylate induced
complete hematological remission in a
very high percentage of patients with
chronic-phase CML (26). Although this
drug has become the standard of care for
CML, it is important to note that ima-
tinib mesilate does not cure the disease
(it just keeps it under control for many
patients for as long as they take the
drug) and that some patients treated
with this drug develop resistance to
treatment (27,28). Other targeted thera-
pies have been approved for cancer treat-
ment in recent years; however, none of
these therapies have led to major im-
provements in the survival of patients
with the most common types of cancer. It
is important to be reminded that cancer
mortality has not changed much during
the last three decades (29), and that the
small declines observed in recent years
in some types of cancer (that is, lung, co-
lorectal, breast and prostate cancer) are
not attributable only to better therapies
but also to the implementation of pre-
vention and early detection campaigns
(30,31).
Although the genetic alterations of
tumor cells are extremely numerous and
unstable (12,13,21), we are moving to-
ward an era of personalized treatments
based on the genetic profile of each
tumor (22–24). It is expected that much
time and effort and many resources will
be necessary to develop therapies that
will be useful in a small percentage of
patients with cancer. In addition to
building up a complex array of genetic
changes, tumor cells acquire an alteration
in the metabolism of oxygen, a process
that plays an important role in carcino-
genesis and could be exploited to de-
velop therapies for a broad range of pa-
tients with cancer.
KEY ROLE OF ALTERED OXYGEN
METABOLISM IN CANCER
Nonmalignant cells use oxygen (O2) to
generate energy in the form of ATP
through the process of oxidative phos-
phorylation (oxphos). Accumulating evi-
dence indicates that, instead of fully cou-
pling the metabolism of O2 with the
generation of energy, cancer cells activate
glycolysis to meet their energy demands
and use O2 to generate excessive levels of
the reactive oxygen species (ROS) super-
oxide anion (O2
•–) and hydrogen perox-
ide (H2O2). This alteration in the metabo-
lism of O2 (dysoxic metabolism) is a
common feature of cancer cells and plays
an important role in carcinogenesis
(32–38).
It is well known that uncontrolled cell
proliferation is the most relevant feature
of cancer. It is also recognized that the
genetic defects of cancer cells result in an
altered gene expression and in the pro-
duction of signals that make these cells
proliferate in an uncontrolled fashion.
Equally important for cell proliferation is
that the dividing cell duplicates all its
cellular components to create two
daughter cells (Figure 1A). To do this,
proliferating cells must take nutrients
from the blood and use them to synthe-
size all the macromolecules and cellular
components required for the formation
of a new cell. The cellular uptake of glu-
cose from the blood and the activation of
glycolysis are essential processes for cell
proliferation, because the activation of
glycolysis provides most of the building
blocks required for the synthesis of these
macromolecules and cellular components
(37). Several glycolytic enzymes are over-
expressed in cancer cells and have been
shown to play an important role in can-
cer (39–41). The increased cellular uptake
of glucose and the upregulation of gly-
colysis of cancer cells can indeed be ob-
served with clinical tumor imaging (fluo-
rodeoxyglucose positron-emission
tomography) and is currently used for
early diagnosis and better management
of oncology patients (42).
The fact that the blood vessels deliver
both glucose and O2 is a problem for the
activation of glycolysis, because the
presence of O2 is known to cause glycol-
ysis inhibition (Pasteur effect). This situ-
ation suggests that to proliferate cancer
cells must develop the capacity to acti-
vate glycolysis in the presence of O2
(Figure 1A), a characteristic that was
first observed several decades ago by
the Nobel laureate Otto Warburg. War-
burg also proposed that the high gly-
colytic rates he observed in cancer cells
despite the presence of O2 were caused
by a defect in respiration (oxidative
phosphorylation) and that this defect
was the origin of cancer (43).
Although the activation of glycolysis
in the presence of O2 (aerobic glycolysis
or the Warburg effect) has repeatedly
been observed in cancer cells (37,42,44),
it is not clear why and how this phenom-
enon occurs. I first proposed that to pro-
liferate cancer cells (and normal prolifer-
ating cells) must activate glycolysis
despite the presence of O2 (33,37). As
shown in Figure 1A, cell proliferation
would be compromised if glycolysis
were always inhibited in the presence of
O2 (33,37). The same proposal was later
made by others (45). As to how this phe-
nomenon occurs, evidence suggests that
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Figure 1. Cancer development requires both the acquisition of DNA alterations and a change in the metabolism of oxygen (dysoxic me-
tabolism). (A) The uncontrolled cell proliferation that characterizes cancer requires signals for cell proliferation and the synthesis of new
macromolecules (for example, nucleic acids, lipids, proteins). Glycolysis provides building blocks (for example, glucose 6-phosphate, dihy-
droxyacetone phosphate, 3-phosphoglycerate, phosphoenolpyruvate, pyruvate) that participate in the synthesis of these macromole-
cules. The presence of O2 can inhibit glycolysis (Pasteur effect) and, therefore, the biosynthesis of new macromolecules required for the
uncontrolled cell proliferation that characterizes cancer. (B) A change in the metabolism of O2 (dysoxic metabolism) would allow the ac-
tivation of glycolysis in the presence of O2 and, therefore, cell proliferation and cancer development.
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the change in the metabolism of O2
(dysoxic metabolism) (Figure 1B) is cru-
cial for the activation of glycolysis in the
presence of O2 (37). Briefly, high ATP lev-
els repress glycolysis via allosteric inhibi-
tion of phosphofructokinase, a key en-
zyme in the regulation of glycolysis. The
possible basis of the Pasteur effect is that
the presence of O2 allows ATP synthesis
through oxphos, which causes an al-
losteric inhibition of phosphofructoki-
nase resulting in the inhibition of glycol-
ysis. This proposed mechanism suggests
that glycolysis is not directly inhibited by
O2, but by ATP, and that the presence of
O2 will not cause the inhibition of glycol-
ysis when O2 is not used to generate
enough ATP (37). The metabolic switch
from oxphos to glycolysis commonly ob-
served in cancer cells (43,46–48), along
with the increased production of O2
•–
and H2O2 found in these cells (49–53),
supports the idea that cancer cells have
this alteration in the metabolism of O2.
This alteration may play a crucial role in
carcinogenesis by allowing the activation
of glycolysis in the presence of O2 and,
therefore, the uncontrolled cell prolifera-
tion that characterizes cancer (Figure 1B).
A deviation of the metabolism of O2
from the pathway that generates ATP to
the pathway that generates ROS may be
necessary for cell proliferation and tumor
growth (Figure 1B) (33,37). Evidence sug-
gests that this metabolic switch may also
play an important role in tumor metasta-
sis (34). Hypoxia-inducible factor 1
(HIF-1) is a key regulator of O2 homeo-
stasis, and the activation of HIF-1 is
known to play a vital role in the most
relevant aspects of carcinogenesis, in-
cluding cell survival, angiogenesis, inva-
sion, metastasis, cellular immortalization
and metabolic reprogramming (54–56).
Because an increased production of H2O2
(57) and the accumulation of glycolytic
metabolites (58) are known to activate
HIF-1, it has been proposed that the
dysoxic metabolism represented in Fig-
ure 1B may play an important role in the
activation of HIF-1 (32). This dysoxic me-
tabolism results in increased production
of O2
•– and H2O2, and evidence suggests
that the accumulation of these ROS
causes oxidative stress and plays an im-
portant role in carcinogenesis (35,36, 59,
60). The key role of ROS in carcinogene-
sis is supported by experimental data
showing that cancer cells commonly
have increased levels of ROS (49–53),
that ROS can induce cell malignant
transformation (61,62) and that the ma-
lignant phenotype of cancer cells can be
reversed by reducing the cellular levels
of ROS (63–68). Overall, evidence sug-
gests that the alteration in the metabo-
lism of O2 represented in Figure 1B is a
common feature of cancer cells and may
play a key role in carcinogenesis (32–38).
A NEW MODEL OF CARCINOGENESIS
The most accepted model of carcino-
genesis postulates that tumorigenesis is
caused by DNA alterations and that can-
cer can be treated by reversing or ex-
ploiting these alterations (Figure 2A). A
new model of carcinogenesis is proposed
in Figure 2B. According to this new
model, the development of any cancer
requires that the future tumor cell both
acquires a complex set of DNA alter-
ations and develops an alteration in the
metabolism of O2. It is widely acknowl-
edged that the altered genome of tumor
cells plays a key role in carcinogenesis.
Evidence suggests that an alteration in
the metabolism of O2 from the pathway
that generates energy to the pathway
that produces ROS may also play an im-
portant role in the development of cancer
(discussed in this review). This new
model considers that both alterations
must cooperate for the formation of a
cancer; the acquisition of DNA alter-
ations leads to an alteration in the metab-
olism of O2 and vice versa. Indeed, there
is evidence that the transition from a nor-
mal to a malignant phenotype brought
about by cancer-causing genes is associ-
ated with a progressive energy switch
from oxphos to glycolysis (69). Alter-
ations in p53, one of the most frequently
mutated tumor-suppressor genes in can-
cer, have also been proposed to partici-
pate in the metabolic switch from oxphos
to glycolysis (48). Mitochondrial muta-
tions may reduce the activity of oxphos
and have been associated with an in-
crease in the cellular production of ROS
(70). The activation of several oncogenes
is also known to increase the cellular
production of O2
•– and H2O2 (71–74).
Conversely, an alteration in the metabo-
lism of O2 (from the pathway that gener-
ates ATP to the pathway that generates
O2
•– and H2O2) can lead to the acquisi-
tion of DNA alterations. H2O2 is indeed
well known to induce DNA alterations,
Figure 2. Models of carcinogenesis. In addition to the acquisition a complex array of DNA
alterations proposed in the accepted model of carcinogenesis (A), the model discussed
in this review (B) proposes that cancer develops an alteration in the metabolism of oxy-
gen. Although both changes must interact for the development of cancer, the altered
oxygen metabolism of tumor cells is not subject to the high genetic complexity and vari-
ability of tumors and may therefore be a more reliable target for cancer therapy.
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including DNA damage, mutations and
genetic instability (75–78).
Most carcinogenic agents have been
shown to induce DNA alterations. Most
carcinogenic agents also induce oxidative
stress (38,79), and a deviation in the me-
tabolism of O2 toward the pathway that
generates ROS is a key feature of oxida-
tive stress (38,60,79). An example of how
a carcinogenic agent can induce both
DNA alterations and an alteration in the
metabolism of O2 is shown in Figure 3.
Most chemical carcinogens need to be
enzymatically activated to become geno-
toxic, and the cytochrome P450 (P450)
enzymes are the most prominent en-
zymes involved in such activation (80).
The activity of P450 enzymes is associ-
ated with the generation of O2
•– and
H2O2 (81), and H2O2 is well known to in-
duce DNA alterations (75–78). An in-
crease in the generation of H2O2 is associ-
ated with the activation of HIF-1 (32,57),
which can lead to the repression of ox-
phos and the activation of glycolysis
(82,83). The accumulation of glycolytic
intermediates caused by the activation of
glycolysis can also increase the activity
of HIF-1 (58) (Figure 3). Carcinogenic
agents can induce DNA alterations and
an altered O2 metabolism independently
of P450. For instance, the increase in the
intracellular pH induced by some car-
cinogenic agents seems to be crucial for
the development of cancer (84,85). A rise
in the intracellular pH can increase the
production of O2
•– (86) and lead to DNA
alterations and a dysoxic metabolism
through the pathways represented in
Figure 3. Because exposure to many
other carcinogenic factors has been asso-
ciated with an increased production of
ROS (38,59,79), these carcinogenic factors
may also lead to DNA alterations and a
dysoxic metabolism through the path-
ways represented in Figure 3.
According to the most accepted model
of carcinogenesis, the DNA alterations of
tumor cells are a target for cancer ther-
apy (Figure 2A). However, as discussed
in above, the high number and variabil-
ity of these DNA alterations is an obsta-
cle for the design of gene-based therapies
that may have a major impact on cancer
mortality (12,21). The importance of the
new model of carcinogenesis represented
in Figure 2B is that it offers an alternative
target for the treatment of cancer, which
is not subject to the high genetic variabil-
ity of tumor cells and may therefore be
more easily targeted. How the altered O2
metabolism of cancer could be used ther-
apeutically to kill tumor cells selectively
is discussed in the following section.
TARGETING THE ALTERED OXYGEN
METABOLISM OF TUMOR CELLS FOR THE
TREATMENT OF CANCER
Tumor cells and normal cells metabo-
lize O2 differently; this difference could
be exploited to target tumor cells selec-
tively (Figure 4). Normal cells have full
oxphos capacity, low production of H2O2
and glycolysis inhibition in the presence
of O2. Normal cells do not need to main-
tain high glycolytic activity to ensure
their survival. Cancer cells have an alter-
Figure 3. Carcinogenic agents can induce DNA alterations and an alteration in the me-
tabolism of oxygen. This figure represents an example of how a carcinogenic agent can
induce both DNA alterations and a dysoxic metabolism via P450. See text for references
and further details.
Figure 4. Utility of the altered oxygen metabolism of cancer cells to selectively kill them.
Cancer cells and normal cells metabolize oxygen differently. Because the basal levels of
H2O2 are higher in cancer cells than in normal cells, a specific increase in the concentra-
tions of H2O2 may lead to cytotoxic concentrations in cancer cells but not in normal cells.
In addition, because the activation of glycolysis in cancer cells is essential to prevent cell
death induced by ATP depletion and H2O2 accumulation, the attenuation of glycolysis in
cancer cells can induce their death. Normal cells would be less affected by this strategy,
because they do not need to have increased glycolytic rates to ensure their survival. See
text for further details. Dotted lines indicate that the pathway or process is repressed.
Bolded lines indicate that the process is activated or that the levels of the molecule are
increased.
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ation in the metabolism of O2 (dysoxic
metabolism), which is associated with
oxphos repression, increased production
of H2O2 and increased glycolytic activity.
The high glycolytic activity of cancer
cells is essential for their survival, be-
cause it prevents cell death induced by
ATP depletion and H2O2 accumulation.
The dysoxic metabolism of cancer cells
can be exploited to kill cancer cells selec-
tively by increasing the cellular levels of
H2O2 and/or by attenuating glycolysis.
These effects could be achieved by the
use of prooxidant agents and glycolysis
inhibitors, alone or in combination.
Selective Killing of Cancer Cells by
H2O2 and Prooxidant Agents
Recent data suggest that oxidative
stress may play a role in the anticancer
activity of many chemotherapeutic
agents commonly used in cancer treat-
ment, including paclitaxel, cisplatin, dox-
orubicin, arsenic trioxide, bortezomib,
procarbazine and etoposide (87–101). For
instance, although it has been known for
many years that the microtubule protein
tubulin is the therapeutic target for pacli-
taxel (taxol), recent experiments have
shown that H2O2 plays an important role
in paclitaxel-induced cancer cell death
(87,89). The role of ROS in the activity of
many anticancer agents is increasingly
being acknowledged, and the induction
of oxidative stress by prooxidant agents
is emerging as an attractive anticancer
strategy (36,94,99,102–106).
H2O2 seems to be a key player in ox-
idative stress–induced cancer cell death.
Many anticancer agents, such as pacli-
taxel, doxorubicin and arsenic trioxide,
produce H2O2 (87,90,92), and H2O2 is
known to be an efficient inducer of cell
death in cancer cells (36,93,107). Interest-
ingly, cancer cells seem more susceptible
to H2O2-induced cell death than nonma-
lignant cells (108–110). Investigating sev-
eral cancer and normal cell lines, Chen et
al. (108) observed that high concentra-
tions of ascorbic acid selectively killed
cancer cells and that this effect was medi-
ated by H2O2. They showed, for instance,
that a concentration of 50 μmol/L H2O2
induced a higher percentage of cell
death in Burkitt lymphoma cells than
250 μmol/L in normal lymphocytes and
normal monocytes (108). In vitro and in
vivo data indicate that tumor cells pro-
duce higher concentrations of H2O2 than
their normal counterparts (49–53). These
data, and the fact that there is a threshold
of H2O2 above which cells cannot sur-
vive, may explain why specific concentra-
tions of H2O2 induce selective killing of
cancer cells (36). Overall, evidence sug-
gests that increasing the levels of H2O2 in
cancer cells by using prooxidant agents
may be an important therapeutic strategy.
The concentration of a prooxidant agent
required to generate levels of H2O2 that
kill cancer cells but not normal cells
could be determined in cell culture exper-
iments. Then, by using an appropriate
route of administration, such concentra-
tions should be achieved in vivo to ob-
serve a selective antitumor effect.
Selective Killing of Cancer Cells by
Glycolysis Inhibition
The increased glycolytic activity of
cancer cells seems to be important for
keeping adequate energy levels in these
cells. Xu et al. (111) observed that the in-
hibition of glycolysis severely depleted
ATP in cancer cells and induced cell
death, especially in cancer cells with mi-
tochondrial respiration defects. The de-
pendence of cancer cells on glycolytic en-
ergy seems to increase as malignant
transformation occurs (69). It has been
proposed that this increased dependence
on glycolysis for energy generation is an
important metabolic difference between
normal and malignant cells that may
serve for developing therapeutic strate-
gies to preferentially kill cancer cells
(44,112,113). Several glycolysis inhibitors
have shown anticancer effects (for exam-
ple, 2-deoxy-D-glucose, lonidamine,
3-bromopyruvate and dichloroacetate)
and some of them have entered the clini-
cal trial stage of investigation (37,44,112,
114). For example, it has been shown that
dichloroacetate, a known glycolysis in-
hibitor that has been used in humans for
decades in the treatment of lactic acidosis
and inherited mitochondrial diseases, in-
duced marked anticancer effects in mice
(115). The authors found that dichloroac-
etate in the drinking water at clinically
relevant doses for up to 3 months pre-
vented and reversed tumor growth in
vivo, without apparent toxicity and with-
out affecting hemoglobin, transaminase
or creatinine levels. They concluded that
the ease of delivery, selectivity and effec-
tiveness of dichloroacetate make this
agent an attractive candidate for cancer
therapy, one that can be rapidly trans-
lated into phase II–III clinical trials (115).
Other strategies could be used to inhibit
or exploit the increased glycolytic activ-
ity of cancer cells. Because an increase in
the activity of the Na+/K+-ATPase pump
is associated with the activation of gly-
colysis (116,117), the inhibition of this
pump (for example, by cardiac glyco-
sides) may result in the inhibition of gly-
colysis and the selective killing of cancer
cells (113,118). The activation of glycoly-
sis is known to increase the concentra-
tion of protons in the cytosol. These pro-
tons must be extruded to prevent
acid-induced cell death. The inhibition of
the cellular systems involved in the ex-
trusion of protons in cancer cells may
also lead to the selective killing of cancer
cells (119).
Combination of Prooxidant Agents
with Glycolysis Inhibitors for
Anticancer Therapy
Although ROS can induce cancer cell
death, tumor cells are known to develop
mechanisms that prevent ROS from
reaching cytotoxic levels. The glu-
tathione and thioredoxin antioxidant
systems are crucial for detoxifying ROS.
These antioxidant systems are activated
in cancer cells and play an important
role in the development of resistance to
many anticancer agents (120–126). Like-
wise, although the inhibition of glycoly-
sis is an attractive anticancer strategy, in
vivo experiments suggest that the inhibi-
tion of glycolysis may not be sufficient
to induce potent anticancer effects. Ac-
cordingly, although the glycolysis in-
hibitor 2-deoxy-D-glucose is an efficient
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inducer of cell death in vitro (127), its an-
ticancer in vivo activity is not very high
when it is used as a single agent. The an-
ticancer activity of 2-deoxy-D-glucose
has been explored in combination with
chemotherapeutic drugs and radiation,
and some of these combinations have
entered clinical trials (44,112,128–132).
Prooxidant agents could be combined
with glycolysis inhibitors to maximize
their anticancer activity. Evidence indi-
cates that prooxidant agents can increase
the cellular levels of H2O2 and that gly-
colysis inhibitors can reduce the capacity
of cells to detoxify H2O2. Experimental
data have shown that malignant cells are
more susceptible to glucose deprivation
than nontransformed cells, and that an
increase in the levels of H2O2 may medi-
ate the cytotoxic effect induced by glu-
cose deprivation (53,133–135). Two possi-
ble mechanisms may explain why the
activation of glycolysis performs an im-
portant function in protecting tumor cells
from H2O2-induced cell death. First, the
activation of glycolysis increases the for-
mation of pyruvate, which is an efficient
scavenger of H2O2 (136–139). Second,
glucose metabolism through the pentose
phosphate pathway regenerates NADPH
from NADP+ in a reaction in which
 glucose-6-phosphate is converted into
6-phosphogluconolactone by the enzyme
glucose-6-phosphate dehydrogenase. The
regeneration of NADPH is required for
H2O2 detoxification through the glu-
tathione peroxidase/glutathione reduc-
tase system and through the thioredoxin
peroxidase/thioredoxin reductase sys-
tem (134,140,141) (Figure 5).
CONCLUSIONS
Cancer kills more than six million peo-
ple worldwide every year (142). The
mortality rate of this disease has not
changed much in the past few decades
even in developed countries such as the
United States (29). The small decreases
observed in recent years in some types of
cancer (29) are not attributable only to
better therapies, but also to the imple-
mentation of prevention and early detec-
tion campaigns. The goal of these cam-
paigns is to make people aware that
many cancers can be prevented by fol-
lowing several guidelines, and that can-
cer therapy is effective when this disease
is detected early (30,31). Despite these
campaigns, many cancers are still diag-
nosed when cells from a primary tumor
have already metastasized to other parts
of the body. At this stage of disease,
tumor cells are no longer localized and
can no longer be eliminated by surgery
or radiotherapy. The main form of treat-
ment at this point is chemotherapy,
which consists of delivering drugs sys-
temically so that they can reach and kill
the tumor cells. But most of these drugs
are toxic to both tumor and normal cells,
cause severe side effects in patients and,
therefore, need to be used at suboptimal
levels. The low efficacy of chemotherapy
in patients with advanced cancers is re-
flected in the low 5-year survival rates
observed in these patients (29). For in-
stance, cancer statistics show that the
most commonly diagnosed cancer in the
world is lung cancer (142), that approxi-
mately 50% of patients diagnosed with
lung cancer have distant metastasis (29)
and that only 3% of these patients man-
age to survive more than 5 years (29).
The low efficacy of cancer therapy for
the treatment of patients with metastasis
makes the development of novel thera-
peutic approaches necessary.
A novel therapeutic approach has
emerged strongly in recent years. This
approach seeks to attack the tumor cells
selectively and is based on understand-
ing of the differences between tumor
cells and nonmalignant cells. It has been
known for many years that tumor cells
have genetic alterations and much re-
search has been done to identify these al-
terations. Recent analyses of human can-
cers have revealed, however, that the
genetic defects of tumor cells are much
Figure 5. Key role of glycolysis in the detoxification of H2O2. Increased glucose metabolism
helps detoxify H2O2 by increasing the levels of the H2O2 scavenger pyruvate and by re-
generating NADPH. Glutathione reductase (GR) and thioredoxin reductase (TrxR) need
NADPH to regenerate glutathione (GSH) and thioredoxin [Trx(SH)2], which are used by glu-
tathione peroxidase (GPx) and thioredoxin peroxidase (TPx) to detoxify H2O2. Thiol (SH)-
 reactive agents can react with the SH groups of GSH and Trx(SH)2 and induce a prooxi-
dant effect by disrupting the GR/GPx and TrxR/TPx antioxidant systems.
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more numerous and unstable than ex-
pected (12,13). In addition, the genetic al-
terations of tumor cells are not the same
in different types of cancer or even in
different people with the same type of
cancer. Given these circumstances it will
probably be very difficult to develop fu-
ture gene-based therapies that may be
useful in a wide range of patients with
cancer (12,20,21). Despite the complexity
of the cancer genome, much research is
devoted to characterizing the genetic
profile of tumors to rationalize and per-
sonalize cancer therapy (22–24).
An alternative approach has been dis-
cussed in this review. In addition to build-
ing up a complex set of DNA changes, ev-
idence suggests that the development of
any cancer requires that tumor cells ac-
quire an alteration in the metabolism of
oxygen. Interestingly, this alteration in the
metabolism of oxygen can make cancer
cells vulnerable to therapeutic interven-
tion. Their increased basal levels of H2O2
and their higher dependence on glycoly-
sis for their survival make cancer cells
more susceptible than normal cells to
treatment with prooxidant agents and
glycolysis inhibitors. Because this alter-
ation in the metabolism of oxygen seems
to be a common feature of tumor cells,
this therapeutic approach could be used
for the treatment of a wide range of pa-
tients with cancer. Future research will re-
veal whether this alternative approach
will be sufficient to increase the survival
of patients with advanced cancers, or
whether it will be necessary to use it in
combination with traditional chemother-
apy and/or novel targeted therapies.
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